Literature DB >> 15286803

Cancer cachexia is regulated by selective targeting of skeletal muscle gene products.

Swarnali Acharyya1, Katherine J Ladner, Lori L Nelsen, Jeffrey Damrauer, Peter J Reiser, Steven Swoap, Denis C Guttridge.   

Abstract

Cachexia is a syndrome characterized by wasting of skeletal muscle and contributes to nearly one-third of all cancer deaths. Cytokines and tumor factors mediate wasting by suppressing muscle gene products, but exactly which products are targeted by these cachectic factors is not well understood. Because of their functional relevance to muscle architecture, such targets are presumed to represent myofibrillar proteins, but whether these proteins are regulated in a general or a selective manner is also unclear. Here we demonstrate, using in vitro and in vivo models of muscle wasting, that cachectic factors are remarkably selective in targeting myosin heavy chain. In myotubes and mouse muscles, TNF-alpha plus IFN-gamma strongly reduced myosin expression through an RNA-dependent mechanism. Likewise, colon-26 tumors in mice caused the selective reduction of this myofibrillar protein, and this reduction correlated with wasting. Under these conditions, however, loss of myosin was associated with the ubiquitin-dependent proteasome pathway, which suggests that mechanisms used to regulate the expression of muscle proteins may be cachectic factor specific. These results shed new light on cancer cachexia by revealing that wasting does not result from a general downregulation of muscle proteins but rather is highly selective as to which proteins are targeted during the wasting state.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15286803      PMCID: PMC484974          DOI: 10.1172/JCI20174

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  63 in total

Review 1.  Cachexia in cancer patients.

Authors:  Michael J Tisdale
Journal:  Nat Rev Cancer       Date:  2002-11       Impact factor: 60.716

Review 2.  Striated muscle cytoarchitecture: an intricate web of form and function.

Authors:  Kathleen A Clark; Abigail S McElhinny; Mary C Beckerle; Carol C Gregorio
Journal:  Annu Rev Cell Dev Biol       Date:  2002-04-02       Impact factor: 13.827

Review 3.  Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states.

Authors:  S H Lecker; V Solomon; W E Mitch; A L Goldberg
Journal:  J Nutr       Date:  1999-01       Impact factor: 4.798

4.  The fine structure of type II muscle fiber atrophy.

Authors:  J R Mendell; W K Engel
Journal:  Neurology       Date:  1971-04       Impact factor: 9.910

5.  Tumor necrosis factor-regulated biphasic activation of NF-kappa B is required for cytokine-induced loss of skeletal muscle gene products.

Authors:  Katherine J Ladner; Michael A Caligiuri; Denis C Guttridge
Journal:  J Biol Chem       Date:  2002-11-12       Impact factor: 5.157

6.  Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy.

Authors:  Marco Sandri; Claudia Sandri; Alex Gilbert; Carsten Skurk; Elisa Calabria; Anne Picard; Kenneth Walsh; Stefano Schiaffino; Stewart H Lecker; Alfred L Goldberg
Journal:  Cell       Date:  2004-04-30       Impact factor: 41.582

7.  TNF-alpha increases ubiquitin-conjugating activity in skeletal muscle by up-regulating UbcH2/E220k.

Authors:  Yi-Ping Li; Stewart H Lecker; Yuling Chen; Ian D Waddell; Alfred L Goldberg; Michael B Reid
Journal:  FASEB J       Date:  2003-06       Impact factor: 5.191

8.  Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression.

Authors:  Stewart H Lecker; R Thomas Jagoe; Alexander Gilbert; Marcelo Gomes; Vickie Baracos; James Bailey; S Russ Price; William E Mitch; Alfred L Goldberg
Journal:  FASEB J       Date:  2004-01       Impact factor: 5.191

9.  The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors.

Authors:  Trevor N Stitt; Doreen Drujan; Brian A Clarke; Frank Panaro; Yekatarina Timofeyva; William O Kline; Michael Gonzalez; George D Yancopoulos; David J Glass
Journal:  Mol Cell       Date:  2004-05-07       Impact factor: 17.970

Review 10.  Cancer cachexia: the molecular mechanisms.

Authors:  Josep M Argilés; Rodrigo Moore-Carrasco; Gemma Fuster; Sílvia Busquets; Francisco J López-Soriano
Journal:  Int J Biochem Cell Biol       Date:  2003-04       Impact factor: 5.085

View more
  195 in total

1.  The isolated muscle fibre as a model of disuse atrophy: characterization using PhAct, a method to quantify f-actin.

Authors:  William J Duddy; Tatiana Cohen; Stephanie Duguez; Terence A Partridge
Journal:  Exp Cell Res       Date:  2011-05-20       Impact factor: 3.905

Review 2.  Models of accelerated sarcopenia: critical pieces for solving the puzzle of age-related muscle atrophy.

Authors:  Thomas W Buford; Stephen D Anton; Andrew R Judge; Emanuele Marzetti; Stephanie E Wohlgemuth; Christy S Carter; Christiaan Leeuwenburgh; Marco Pahor; Todd M Manini
Journal:  Ageing Res Rev       Date:  2010-05-14       Impact factor: 10.895

Review 3.  Metabolic benefits of resistance training and fast glycolytic skeletal muscle.

Authors:  Nathan K LeBrasseur; Kenneth Walsh; Zoltan Arany
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-11-02       Impact factor: 4.310

4.  Chronic heart failure decreases cross-bridge kinetics in single skeletal muscle fibres from humans.

Authors:  Mark S Miller; Peter VanBuren; Martin M LeWinter; Joan M Braddock; Philip A Ades; David W Maughan; Bradley M Palmer; Michael J Toth
Journal:  J Physiol       Date:  2010-08-19       Impact factor: 5.182

Review 5.  The emerging role of skeletal muscle oxidative metabolism as a biological target and cellular regulator of cancer-induced muscle wasting.

Authors:  James A Carson; Justin P Hardee; Brandon N VanderVeen
Journal:  Semin Cell Dev Biol       Date:  2015-12-01       Impact factor: 7.727

6.  The Toll-Like Receptor/MyD88/XBP1 Signaling Axis Mediates Skeletal Muscle Wasting during Cancer Cachexia.

Authors:  Kyle R Bohnert; Praneeth Goli; Anirban Roy; Aditya K Sharma; Guangyan Xiong; Yann S Gallot; Ashok Kumar
Journal:  Mol Cell Biol       Date:  2019-07-16       Impact factor: 4.272

Review 7.  [Intensive care unit-acquired weakness in the critically ill : critical illness polyneuropathy and critical illness myopathy].

Authors:  K Judemann; D Lunz; Y A Zausig; B M Graf; W Zink
Journal:  Anaesthesist       Date:  2011-10       Impact factor: 1.041

8.  JNK signaling contributes to skeletal muscle wasting and protein turnover in pancreatic cancer cachexia.

Authors:  Scott E Mulder; Aneesha Dasgupta; Ryan J King; Jaime Abrego; Kuldeep S Attri; Divya Murthy; Surendra K Shukla; Pankaj K Singh
Journal:  Cancer Lett       Date:  2020-07-28       Impact factor: 8.679

9.  The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity.

Authors:  Jun-ichi Hanai; Peirang Cao; Preeti Tanksale; Shintaro Imamura; Eriko Koshimizu; Jinghui Zhao; Shuji Kishi; Michiaki Yamashita; Paul S Phillips; Vikas P Sukhatme; Stewart H Lecker
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

10.  Understanding tumor anabolism and patient catabolism in cancer-associated cachexia.

Authors:  Alejandro Schcolnik-Cabrera; Alma Chávez-Blanco; Guadalupe Domínguez-Gómez; Alfonso Dueñas-González
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.